Innovent's Dual Cancer Innovation Platform Shows Breakthrough Results in Clinical Trials

Innovent Biologics Showcases "Dual Innovations" at Oncology R&D Day, Pioneering the Future of Cancer Treatment with Next-Generation IO and ADC Platforms

SAN FRANCISCO and SUZHOU, China, June 30, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, ophthalmology, and other major…

Boosting Oncology Trials: LLM Accuracy Meets Unprecedented Speed

AI streamlines patient identification for clinical trials, significantly reducing review time while maintaining high accuracy, transforming oncology workflows.

Innovent's Dual Cancer Innovation Platform Shows Breakthrough Results in Clinical Trials

Revolutionary IO-ADC combination shows 70% survival rate in resistant cancers. Innovent's dual-platform strategy targets untreatable tumors. See latest trial data.